UK First in Europe to Approve Lilly's Foundayo Pill

The UK’s medicines regulator has become the first in Europe to authorise Eli Lilly’s oral GLP-1 pill orforglipron, branded Foundayo, clearing the once-daily tablet for weight management and type 2 diabetes on 10 August 2026 — roughly four months after the drug won approval in the United States. The decision puts the UK ahead of the European Medicines Agency, which has not yet ruled on the same molecule for the EU’s centralised market.

Why a pill changes the calculus

Every GLP-1 receptor agonist approved to date has either been an injectable peptide — semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound) — or an oral peptide requiring a strict absorption-enhancing regimen, as with Rybelsus. Orforglipron breaks that pattern: it is a small, non-peptide molecule that survives the gut without an absorption enhancer, so Lilly was able to formulate it as an ordinary tablet with no cold-chain storage, no injection device, and no fasting window. For a regulator and a health system alike, that changes more than convenience — it changes manufacturing scale-up, distribution, and the population a prescriber can realistically reach through routine primary care rather than specialist injectable clinics.

What MHRA actually authorised

The marketing authorisation covers two adult indications: weight loss and weight maintenance in people with a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight-related comorbidity, used together with a reduced-calorie diet and increased physical activity; and improving glycaemic control in adults with type 2 diabetes that is not adequately controlled. MHRA said it granted the authorisation “following rigorous assessment of orforglipron’s safety, quality, and effectiveness,” and that as with all GLP-1 receptor agonists, the medicine is prescription-only and will be kept “under close review” for safety and effectiveness. That review commitment is standard for the drug class, which has drawn ongoing post-marketing scrutiny across its injectable predecessors for gastrointestinal tolerability and rare but serious adverse events.

Off the NHS, for now

MHRA’s authorisation establishes that Foundayo may be prescribed in the UK; it does not establish that the NHS will pay for it. That separate judgment sits with NICE, whose technology appraisal of orforglipron for managing overweight and obesity is still in development and due to publish 18 November 2026. Until NICE reports, and assuming a positive recommendation, NHS patients do not have a funded route to the drug — access runs through private prescription, the same pathway that has carried the UK’s injectable GLP-1 market to date. Eli Lilly has not published UK list pricing.

The rest of Europe is still waiting

MHRA operates independently of the EU’s centralised procedure since Brexit, which is why the UK can move first: a single national assessment, rather than the EMA’s CHMP opinion followed by European Commission decision across all member states at once. The EMA has not published a CHMP opinion on orforglipron, and August is typically a light month for the committee, which replaces its in-person meeting with a written procedure. Sponsors watching for EU-wide access to Foundayo have no published timeline yet; the UK authorisation is a leading indicator, not a substitute.